Compare Stocks → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:CBIONASDAQ:ODTNASDAQ:ONCYOTCMKTS:PFSCF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$7.18-2.2%$6.52$2.65▼$9.01$196.37M1.49343,475 shs133,337 shsCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsODTOdonate Therapeutics$1.27$0.85▼$7.10N/AN/AN/A87,682 shsONCYOncolytics Biotech$1.04+1.0%$1.09$0.88▼$3.39$78.44M1.94398,496 shs147,835 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/A20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-0.27%-2.52%-2.65%+42.80%+164.03%CBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,936.58%ODTOdonate Therapeutics0.00%0.00%0.00%0.00%0.00%ONCYOncolytics Biotech+1.98%+1.98%+4.05%-24.26%-14.88%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics4.1324 of 5 stars3.51.00.04.52.82.50.6CBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech2.6499 of 5 stars3.55.00.00.02.90.00.6PFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$38.00429.25% UpsideCBIOCatalyst BiosciencesN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AONCYOncolytics Biotech3.00Buy$5.00380.77% UpsidePFSCFProMetic Life SciencesN/AN/AN/AN/ACurrent Analyst RatingsLatest PFSCF, ONCY, ABEO, ODT, and CBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.001/19/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.001/12/2024ONCYOncolytics BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight1/4/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M56.11N/AN/A$0.60 per share11.97CBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00ODTOdonate TherapeuticsN/AN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/APFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)CBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%4/4/2024 (Estimated)ODTOdonate Therapeutics-$126.35MN/A0.00N/AN/AN/AN/AN/AN/AONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ACBIOCatalyst BiosciencesN/AN/AN/AN/AN/AODTOdonate TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15CBIOCatalyst BiosciencesN/A2.882.88ODTOdonate TherapeuticsN/AN/AN/AONCYOncolytics BiotechN/A9.019.01PFSCFProMetic Life SciencesN/A0.950.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%CBIOCatalyst Biosciences5.98%ODTOdonate TherapeuticsN/AONCYOncolytics Biotech6.82%PFSCFProMetic Life Sciences0.10%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%CBIOCatalyst Biosciences2.92%ODTOdonate Therapeutics48.90%ONCYOncolytics Biotech0.10%PFSCFProMetic Life SciencesN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionableODTOdonate Therapeutics14528.53 million14.58 millionNot OptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionablePFSCFProMetic Life Sciences48723.31 millionN/ANot OptionablePFSCF, ONCY, ABEO, ODT, and CBIO HeadlinesSourceHeadlinePlant Sciencesuwyo.edu - August 10 at 6:57 PMSocial Sciencesnews.yale.edu - July 29 at 11:52 AMOvercoming DNA Degradation in Forensic Sciencenews-medical.net - June 7 at 9:18 AMThe UK Life Sciences Real Estate Annual Conferencebisnow.com - February 23 at 3:33 AMNew 200-acre Life Sciences Development Proposed in Planodmagazine.com - February 15 at 11:13 PMLife Sciences Keeps Boston as a Top 10 Marketglobest.com - January 29 at 12:55 PMThere's Been No Shortage Of Growth Recently For TMC Life Sciences Berhad's (KLSE:TMCLIFE) Returns On Capitalfinance.yahoo.com - January 29 at 12:55 AMIndia's Glenmark Life Sciences Q3 profit rises 1% on API strengthreuters.com - January 29 at 12:55 AMUS Life Sciences Market Ends 2022 on Solid Ground: Reportcommercialobserver.com - January 29 at 12:55 AMOpportunities aplenty in the life sciences sectoririshtimes.com - January 5 at 8:24 AMLife Sciences Funds Post Mixed Results in Septemberinstitutionalinvestor.com - October 16 at 7:03 PMWhat Recession? Life Sciences Continues To Boomglobest.com - September 24 at 8:17 AMHere's what to expect from Prometic Life Sciences's earnings reportmarkets.businessinsider.com - May 10 at 12:09 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Catalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Odonate TherapeuticsNASDAQ:ODTOdonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.ProMetic Life SciencesOTCMKTS:PFSCFPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.